Iain D. Dukes, D. Phil.
Iain D. Dukes is a Venture Partner with OrbiMed Advisors. He also serves as Chairman of Iovance Biotherapeutics (NASQ: IOVA) and is CEO of Viriom Inc. and Theseus Pharmaceuticals. In addition, Iain is a co-founder and President of Kartos Therapeutics and serves on the Boards of ReViral Limited, NeRRe Therapeutics, KaNDy Therapeutics (where he was formerly Chairman) and ENYO Pharma. Most recently Iain was a Senior Vice President, Business Development & Licensing at Merck & Co. where he oversaw all licensing and M&A deals for Merck Research Laboratories. Iain has more than 20 years of experience in pharmaceutical research, drug discovery, scientific and technology licensing, start-up company leadership, as well as consulting for numerous biotech and venture capital organizations. Before joining Merck, Iain served as vice president of External Research and Development at Amgen. He has also held positions as President and Chief Executive Officer of Essentialis Therapeutics and as Vice President, Scientific and Technology Licensing at GlaxoSmithKline. Iain received his D.Phil. degree from the University of Oxford where he also received a B.A. in Jurisprudence.